{"id":"bcg-instillation-therapy","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Dysuria (painful urination)"},{"rate":"40-60","effect":"Urinary frequency"},{"rate":"20-40","effect":"Hematuria (blood in urine)"},{"rate":"10-20","effect":"Fever"},{"rate":"<1","effect":"Systemic BCG infection (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bacillus Calmette-Guérin (BCG) is a live attenuated mycobacterium administered directly into the bladder where it triggers a robust local immune response, activating dendritic cells, macrophages, and T cells to target and eliminate bladder cancer cells. This immunotherapy approach has been the gold standard for non-muscle-invasive bladder cancer for decades, though the exact mechanisms of anti-tumor immunity remain incompletely understood.","oneSentence":"BCG instillation therapy stimulates the local immune system in the bladder to recognize and destroy cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:49.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-muscle-invasive bladder cancer (NMIBC), high-grade or recurrent"},{"name":"Carcinoma in situ (CIS) of the bladder"}]},"trialDetails":[{"nctId":"NCT07495072","phase":"NA","title":"Early vs Delayed Intravesical Blad-Care During BCG Therapy","status":"RECRUITING","sponsor":"BLAD-HYA Group","startDate":"2025-11-03","conditions":"Urinary Bladder Neoplasms, BCG-Induced Cystitis","enrollment":56},{"nctId":"NCT02138734","phase":"PHASE1, PHASE2","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2014-07-21","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":596},{"nctId":"NCT07483970","phase":"PHASE1","title":"A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2026-03-30","conditions":"High Risk Non-muscle Invasive Bladder Cancer","enrollment":18},{"nctId":"NCT07480356","phase":"PHASE3","title":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Protara Therapeutics","startDate":"2026-05","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":284},{"nctId":"NCT07322263","phase":"PHASE2","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Michael A. O'Donnell","startDate":"2026-04-01","conditions":"Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma","enrollment":174},{"nctId":"NCT07342517","phase":"PHASE3","title":"A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy","status":"WITHDRAWN","sponsor":"Relmada Therapeutics, Inc.","startDate":"2026-06-30","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder","enrollment":""},{"nctId":"NCT04452591","phase":"PHASE3","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","status":"ACTIVE_NOT_RECRUITING","sponsor":"CG Oncology, Inc.","startDate":"2020-10-27","conditions":"Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer","enrollment":190},{"nctId":"NCT07206225","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-06","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":294},{"nctId":"NCT04701151","phase":"PHASE4","title":"NORTH-REG Dwell-Time Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2021-02-03","conditions":"Side Effect of Drug","enrollment":314},{"nctId":"NCT05538663","phase":"PHASE3","title":"Intravesical BCG vs GEMDOCE in NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-02-07","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":870},{"nctId":"NCT06026332","phase":"","title":"ADSTILADRIN Early Utilization and Outcomes in the Real World Setting","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2023-09-15","conditions":"Bladder Cancer","enrollment":202},{"nctId":"NCT06245603","phase":"NA","title":"A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2024-12-20","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":200},{"nctId":"NCT04752722","phase":"PHASE1, PHASE2","title":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","status":"RECRUITING","sponsor":"enGene, Inc.","startDate":"2021-04-22","conditions":"Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":350},{"nctId":"NCT04630730","phase":"PHASE2","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2022-06-24","conditions":"Bladder Cancer","enrollment":46},{"nctId":"NCT07307456","phase":"PHASE2","title":"Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-12-08","conditions":"Bladder Cancer","enrollment":31},{"nctId":"NCT03711032","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-24","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":1397},{"nctId":"NCT05327647","phase":"PHASE2","title":"A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2022-06-23","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":160},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT03945162","phase":"PHASE2","title":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","status":"RECRUITING","sponsor":"Theralase® Technologies Inc.","startDate":"2019-08-30","conditions":"Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG","enrollment":90},{"nctId":"NCT07231809","phase":"NA","title":"Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients","status":"NOT_YET_RECRUITING","sponsor":"AC.TA. S.r.l.","startDate":"2026-01-15","conditions":"Non Muscle Invasive Bladder Cancer, Bladder Cancer, Carcinoma in Situ of Bladder","enrollment":50},{"nctId":"NCT04386746","phase":"PHASE2","title":"Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-07-29","conditions":"Urothelial Carcinoma Bladder, Bladder Cancer","enrollment":27},{"nctId":"NCT06929286","phase":"PHASE3","title":"A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-11","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":125},{"nctId":"NCT03022825","phase":"PHASE2, PHASE3","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2017-06-02","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT06781879","phase":"PHASE4","title":"Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Jakob Kristian Jakobsen","startDate":"2025-06-01","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":272},{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":"Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder","enrollment":106},{"nctId":"NCT06388720","phase":"PHASE2","title":"The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2024-11-19","conditions":"Bladder Cancer","enrollment":82},{"nctId":"NCT05126472","phase":"PHASE1","title":"Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-11-08","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":55},{"nctId":"NCT05519241","phase":"PHASE1","title":"A Phase I Intravesical PPM Therapy for NMIBC","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-10","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":29},{"nctId":"NCT07064863","phase":"PHASE1, PHASE2","title":"A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2025-08-01","conditions":"NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer","enrollment":31},{"nctId":"NCT06816017","phase":"PHASE1","title":"A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2025-06-15","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":""},{"nctId":"NCT02202772","phase":"PHASE1, PHASE2","title":"Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guarionex J. Decastro","startDate":"2014-12-01","conditions":"Urothelial Carcinoma of the Urinary Bladder","enrollment":51},{"nctId":"NCT01697306","phase":"PHASE2","title":"The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer","status":"COMPLETED","sponsor":"A.O.U. Città della Salute e della Scienza","startDate":"2006-09","conditions":"Bladder Cancer","enrollment":120},{"nctId":"NCT03799835","phase":"PHASE3","title":"Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2019-01-17","conditions":"Bladder Cancer","enrollment":517},{"nctId":"NCT06441110","phase":"PHASE3","title":"Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-06-01","conditions":"Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active","enrollment":76},{"nctId":"NCT06427291","phase":"PHASE1","title":"Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-09-21","conditions":"Bladder Cancer","enrollment":20},{"nctId":"NCT04134000","phase":"PHASE1","title":"Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundacion Oncosur","startDate":"2020-02-03","conditions":"Invasive Bladder Cancer","enrollment":40},{"nctId":"NCT06374914","phase":"","title":"Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Dokuz Eylul University","startDate":"2024-04-09","conditions":"Bladder Cancer, BCG, Gemcitabine","enrollment":120},{"nctId":"NCT06324058","phase":"NA","title":"Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-03-18","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT05671900","phase":"NA","title":"Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Clinical Hospital Centre Zagreb","startDate":"2020-04-01","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":70},{"nctId":"NCT06241755","phase":"PHASE3","title":"Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"Chengdu CoenBiotech Co., Ltd","startDate":"2023-12-28","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":412},{"nctId":"NCT06153849","phase":"","title":"Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2023-12-01","conditions":"Bladder Cancer","enrollment":100},{"nctId":"NCT03636256","phase":"PHASE1, PHASE2","title":"Evaluation of NanoDoce® in Participants With Urothelial Carcinoma","status":"COMPLETED","sponsor":"NanOlogy, LLC","startDate":"2019-04-02","conditions":"Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm","enrollment":36},{"nctId":"NCT03171493","phase":"PHASE1","title":"Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy","status":"COMPLETED","sponsor":"Vyriad, Inc.","startDate":"2018-07-20","conditions":"Urothelial Carcinoma","enrollment":8},{"nctId":"NCT02948543","phase":"PHASE3","title":"Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer","status":"UNKNOWN","sponsor":"University of Sydney","startDate":"2013-07","conditions":"Bladder Cancer","enrollment":501},{"nctId":"NCT04943094","phase":"","title":"Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy","status":"UNKNOWN","sponsor":"Aarhus University Hospital","startDate":"2019-09-01","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":50},{"nctId":"NCT05844059","phase":"","title":"Lower Urinary Tract Symptoms After Intravesical Therapy","status":"RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2023-04-21","conditions":"Chemotherapy Effect, Chemotherapeutic Toxicity, Lower Urinary Tract Symptoms","enrollment":60},{"nctId":"NCT02371447","phase":"PHASE1, PHASE2","title":"VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2015-09-08","conditions":"Bladder Cancer","enrollment":39},{"nctId":"NCT02281383","phase":"PHASE2","title":"Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-10","conditions":"Bladder Cancer, High Risk Superficial","enrollment":80},{"nctId":"NCT05675176","phase":"","title":"Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2020-04-12","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":100},{"nctId":"NCT05490082","phase":"PHASE3","title":"Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-03-01","conditions":"Voiding Disorders","enrollment":100},{"nctId":"NCT03091764","phase":"","title":"Evaluation of a Patient-Reported Symptom Index for NMIBC","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2016-07-01","conditions":"Superficial Bladder Cancer","enrollment":498},{"nctId":"NCT04922047","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-06","conditions":"Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms","enrollment":6},{"nctId":"NCT03421236","phase":"PHASE1","title":"Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)","status":"UNKNOWN","sponsor":"Patrice Jichlinski","startDate":"2018-02-18","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":25},{"nctId":"NCT01438112","phase":"PHASE2, PHASE3","title":"Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer","status":"TERMINATED","sponsor":"CG Oncology, Inc.","startDate":"2014-03","conditions":"Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ","enrollment":22},{"nctId":"NCT03664869","phase":"PHASE3","title":"Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2018-10-26","conditions":"Bladder Cancer","enrollment":300},{"nctId":"NCT04798703","phase":"PHASE1","title":"Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)","status":"COMPLETED","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2017-05-24","conditions":"Bladder Carcinoma in Situ (CIS)","enrollment":20},{"nctId":"NCT00462488","phase":"PHASE2","title":"Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ","status":"COMPLETED","sponsor":"Sesen Bio, Inc.","startDate":"2007-03","conditions":"Urinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms","enrollment":46},{"nctId":"NCT03335059","phase":"PHASE3","title":"Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.","status":"TERMINATED","sponsor":"Medical Enterprises Ltd.","startDate":"2019-04-04","conditions":"Bladder Cancer, Bladder Neoplasm, Bladder Tumors","enrollment":5},{"nctId":"NCT04319263","phase":"NA","title":"Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2020-03-01","conditions":"Bladder Cancer","enrollment":1600},{"nctId":"NCT01373294","phase":"PHASE2","title":"Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-11-30","conditions":"Bladder Cancer","enrollment":17},{"nctId":"NCT02202044","phase":"NA","title":"Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2015-02-24","conditions":"Bladder Carcinoma","enrollment":13},{"nctId":"NCT03982797","phase":"PHASE2","title":"Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis","status":"UNKNOWN","sponsor":"Biofabri, S.L","startDate":"2019-05-17","conditions":"Bladder Cancer","enrollment":306},{"nctId":"NCT00595088","phase":"PHASE2","title":"Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"Anchiano Therapeutics Israel Ltd.","startDate":"2008-01","conditions":"Superficial Bladder Cancer","enrollment":47},{"nctId":"NCT01878188","phase":"PHASE1","title":"Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma","status":"COMPLETED","sponsor":"Anchiano Therapeutics Israel Ltd.","startDate":"2013-02","conditions":"Transitional Cell Carcinoma of Bladder","enrollment":38},{"nctId":"NCT03790384","phase":"PHASE4","title":"Sequential Combination Therapy in Bladder Cancer","status":"UNKNOWN","sponsor":"Azienda Ospedaliera \"Sant'Andrea\"","startDate":"2019-01-15","conditions":"Bladder Cancer","enrollment":140},{"nctId":"NCT02471495","phase":"PHASE3","title":"RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)","status":"WITHDRAWN","sponsor":"Medical Enterprises Europe B.V.","startDate":"2016-09","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT01259063","phase":"PHASE1, PHASE2","title":"RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-12","conditions":"Bladder Cancer","enrollment":33},{"nctId":"NCT01200992","phase":"PHASE3","title":"Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer","status":"TERMINATED","sponsor":"Bioniche Life Sciences Inc.","startDate":"2010-11","conditions":"Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma","enrollment":84},{"nctId":"NCT02326168","phase":"EARLY_PHASE1","title":"PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2013-10","conditions":"Bladder Cancer","enrollment":25},{"nctId":"NCT01162785","phase":"PHASE1","title":"1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04","conditions":"Bladder Cancer","enrollment":7},{"nctId":"NCT00406068","phase":"PHASE2, PHASE3","title":"Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Bioniche Life Sciences Inc.","startDate":"2006-11","conditions":"Bladder Neoplasms","enrollment":129},{"nctId":"NCT02254915","phase":"PHASE3","title":"SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I","status":"WITHDRAWN","sponsor":"Medical Enterprises Europe B.V.","startDate":"","conditions":"Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms","enrollment":""},{"nctId":"NCT00384891","phase":"PHASE3","title":"Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer","status":"TERMINATED","sponsor":"Medical Enterprises Europe B.V.","startDate":"2002-02","conditions":"Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urinary Bladder Cancer","enrollment":190},{"nctId":"NCT01442519","phase":"PHASE3","title":"Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"1994-01","conditions":"Bladder Cancer","enrollment":212},{"nctId":"NCT00491296","phase":"","title":"Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2007-06","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT00696579","phase":"PHASE1, PHASE2","title":"Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"University Of Perugia","startDate":"2004-01","conditions":"Bladder Cancer","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BCG","BCG-MEDAC","OncoTICE","ImmuCyst","TheraCys"],"phase":"phase_3","status":"active","brandName":"BCG instillation therapy","genericName":"BCG instillation therapy","companyName":"Turku University Hospital","companyId":"turku-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCG instillation therapy stimulates the local immune system in the bladder to recognize and destroy cancer cells. Used for Non-muscle-invasive bladder cancer (NMIBC), high-grade or recurrent, Carcinoma in situ (CIS) of the bladder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}